Syndax Pharmaceuticals, Inc.’s stock was trading at $20.67 on January 15th. The company has two first-in-class approved therapies, Revuforj and Niktimvo, addressing high unmet medical needs in leukemia and chronic graft-versus-host disease. Syndax has $518 million in cash and investments as of Q2 2025, with strong early commercial traction for Revuforj.

Syndax Pharmaceuticals benefits from a first-mover advantage in Menin inhibition and limited competition in leukemia populations. The company has growing revenue diversification across oncology and immune-mediated diseases, with late-2025 regulatory catalysts and expanding clinical programs. Syndax presents a long-term growth opportunity driven by its cornerstone assets and strategic advantages.

Despite a bullish thesis on Sarepta Therapeutics, Inc. in January 2025, the stock has depreciated by 81.94% due to safety concerns and regulatory uncertainty around Elevidys. BioEquity Watch now emphasizes commercial execution and first-in-class hematology assets at Syndax Pharmaceuticals as a more promising opportunity.

Read more at Yahoo Finance: Syndax Pharmaceuticals, Inc. (SNDX): A Bull Case Theory